Aspira Women’s Health (NASDAQ:AWH) Coverage Initiated at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a note issued to investors on Thursday. The brokerage set a “hold” rating on the stock.

Aspira Women’s Health Stock Performance

NASDAQ:AWH opened at $0.77 on Thursday. Aspira Women’s Health has a 52-week low of $0.67 and a 52-week high of $5.65. The stock has a fifty day moving average of $0.82 and a 200 day moving average of $1.09. The firm has a market capitalization of $12.75 million, a price-to-earnings ratio of -0.64 and a beta of 1.39.

Hedge Funds Weigh In On Aspira Women’s Health

A hedge fund recently bought a new stake in Aspira Women’s Health stock. Pine Valley Investments Ltd Liability Co purchased a new stake in Aspira Women’s Health Inc. (NASDAQ:AWH) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 31,200 shares of the company’s stock, valued at approximately $25,000. Pine Valley Investments Ltd Liability Co owned approximately 0.19% of Aspira Women’s Health as of its most recent SEC filing. 12.19% of the stock is currently owned by hedge funds and other institutional investors.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.